Immunovant Q3 net loss smaller than expected

Overview

• Clinical-stage immunology firm's Q3 net loss beat analyst expectations

• Company completed $550 mln financing, extending cash runway for IMVT-1402 launch

• R&D expenses rose due to IMVT-1402 clinical trial activities

Outlook

• Immunovant expects topline data for IMVT-1402 trials in 2026 and 2027

• Company anticipates batoclimab Phase 3 data in first half of 2026

• Immunovant extends cash runway to support IMVT-1402 launch in Graves’ disease

Result Drivers

• R&D EXPENSES - Increase in R&D expenses primarily due to IMVT-1402 clinical trials and contract manufacturing costs

• FINANCING - $550 mln financing completed, extending cash runway for IMVT-1402 launch

• CLINICAL TRIAL PROGRESS - IMVT-1402 trials across multiple indications remain on track

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Immunovant Inc is $44.00, about 82.9% above its February 5 closing price of $24.06

Press Release: ID:nGNX39KTkZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.